XORTX Therapeutics Inc
XRTX0.400USD
-0.002-0.40%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
2.09MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über XORTX Therapeutics Inc Unternehmen
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
XORTX Therapeutics Inc Informationen
BörsenkürzelXRTX
Name des UnternehmensXORTX Therapeutics Inc
IPO-datumSep 30, 2015
CEODavidoff (Allen W)
Anzahl der mitarbeiter2
WertpapierartOrdinary Share
GeschäftsjahresendeSep 30
Addresse3710 - 33rd Street NW
StadtCALGARY
BörseNASDAQ OMX - NASDAQ BASIC
LandCanada
PostleitzahlT2L 2M1
Telefon14034557727
Websitehttps://www.xortx.com/
BörsenkürzelXRTX
IPO-datumSep 30, 2015
CEODavidoff (Allen W)
Führungskräfte von XORTX Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Stacy Evans, M.D.
Mr. Stacy Evans, M.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Ms. Abigail Jenkins
Ms. Abigail Jenkins
Independent Director
Independent Director
--
--
Mr. Michael Bumby
Mr. Michael Bumby
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Fri, Feb 6
Aktualisiert: Fri, Feb 6
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Lincoln Alternative Strategies LLC
8.22%
Davidoff, Allen Warren
1.73%
Citadel Advisors LLC
1.24%
Baader Bank AG
0.27%
XTX Markets LLC
0.20%
Andere
88.34%
Aktionäre
Aktionäre
Anteil
Lincoln Alternative Strategies LLC
8.22%
Davidoff, Allen Warren
1.73%
Citadel Advisors LLC
1.24%
Baader Bank AG
0.27%
XTX Markets LLC
0.20%
Andere
88.34%
Aktionärstypen
Aktionäre
Anteil
Corporation
8.22%
Individual Investor
1.91%
Hedge Fund
1.24%
Investment Advisor/Hedge Fund
0.27%
Venture Capital
0.20%
Investment Advisor
0.03%
Andere
88.13%
Institutionelle Beteiligung
Aktualisiert: Wed, Jan 21
Aktualisiert: Wed, Jan 21
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q4
10
101.02K
4.75%
--
2025Q4
16
102.18K
1.47%
-649.58K
2025Q3
16
63.97K
1.23%
-645.66K
2025Q2
17
129.44K
3.30%
-739.58K
2025Q1
20
127.29K
3.49%
-606.22K
2024Q4
21
385.20K
10.34%
-244.07K
2024Q3
22
287.39K
12.35%
-145.77K
2024Q2
20
276.67K
12.12%
-141.93K
2024Q1
21
272.84K
13.24%
-121.02K
2023Q4
19
553.49K
27.69%
+481.09K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Lincoln Alternative Strategies LLC
572.47K
8.22%
+572.47K
--
Oct 23, 2025
Davidoff, Allen Warren
120.45K
1.73%
+8.19K
+7.30%
Jul 22, 2025
Citadel Advisors LLC
86.33K
1.24%
+47.86K
+124.41%
Sep 30, 2025
XTX Markets LLC
13.82K
0.2%
+13.82K
--
Sep 30, 2025
Giovinazzo (Anthony)
9.63K
0.14%
--
--
Apr 30, 2025
UBS Financial Services, Inc.
234.00
0%
-20.56K
-98.87%
Sep 30, 2025
RBC Dominion Securities, Inc.
358.00
0.01%
-305.00
-46.00%
Sep 30, 2025
Van Damme (Paul Joseph)
324.00
0%
-6.79K
-95.44%
Oct 17, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Datum
Ex-Dividendentag
Art
Verhältnis
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
